News & Events

News

Pillar in the News

June 4, 2019
Columbia University Medical CenterReceives Conditional Approval by the New York State Department of Healthfor a Custom Pillar Biosciences NGS Panel

BOSTON, May 30, 2019 /PRNewswire/ — Pillar Biosciences, a clinical cancer diagnostics company based near Boston, MA, announced today that the Columbia Solid Tumor Panel, a next-generation sequencing (NGS) panel, [more]

BOSTON, May 30, 2019 /PRNewswire/ -- Pillar Biosciences, a clinical cancer diagnostics company based near Boston, MA, announced today that the Columbia Solid Tumor Panel, a next-generation sequencing (NGS) panel, received conditional approval by the New York State Department of Health for clinical use by the Laboratory of Personalized Genomic Medicine at Columbia University Medical Center (CUMC).

The Columbia Solid Tumor Panel was designed by Dr. Helen Fernandes and colleagues at CUMC and leverages Pillar Biosciences' proprietary SLIMamp® enrichment chemistry and single-tube amplification for an easy workflow to interrogate 47 genes for variants associated with solid tumors, including most mutations labeled as companion diagnostics. Dr. Fernandes and her team have presented validation data at both domestic and international conferences demonstrating robust analytical performance, sensitive variant detection with low DNA input, and a rapid turnaround time from sample to answer.

The Columbia Solid Tumor Panel will be used at the front end of the molecular oncology testing workflow at CUMC. The panel's rapid turnaround time and low DNA input requirements accelerate identification of the most prevalent oncogenic mutations resulting in quicker diagnosis for selection of targeted therapies.

"We evaluated other solid tumor panels and found that the single-tube amplification used in this panel worked best for us in terms of workflow, assay performance, and cost," said Dr. Helen Fernandes, Co-Director of Genomic Oncology at the Laboratory of Personalized Genomic Medicine, Department of Pathology and Cell Biology at CUMC.

"We are happy for Columbia's conditional approval," said Gang Song, Ph.D., Founder and CEO of Pillar Biosciences. "Our mission is to make precision medicine accessible, and we are excited about Columbia's ability to more efficiently leverage lab resources to provide accurate diagnostics to patients with limited time for treatment determination."

Press Contact:

William Wright

Director of Sales

info@pillar-biosciences.com

About Pillar Biosciences

Pillar Biosciences is a clinical cancer diagnostics company based near Boston, Massachusetts. We create precision NGS panels and software solutions to make clinical NGS robust, streamlined and cost-effective. Our SLIMamp®- and PiVAT®-based products are intended to deliver the most value to high-throughput reference laboratories and clinical oncology laboratories. Learn more at pillar-biosciences.com.

SOURCE Pillar Biosciences

Related Links

https://pillar-biosciences.com

Pillar in the News

January 10, 2019
Pillar Biosciences Enters Strategic Partnership With China Biotech Services Holdings to Deliver Precision Diagnostics to Markets in Asia

SAN FRANCISCO, CA, Jan. 10, 2019 /PRNEWSWIRE/ – Pillar Biosciences, Inc., a clinical cancer diagnostics company based in Boston, MA and Shanghai, China, is forming a strategic partnership and joint [more]

SAN FRANCISCO, CA, Jan. 10, 2019 /PRNEWSWIRE/ – Pillar Biosciences, Inc., a clinical cancer diagnostics company based in Boston, MA and Shanghai, China, is forming a strategic partnership and joint venture with China Biotech Services Holdings, Ltd (CBSH; HKSE:08037). The agreement was signed on January 9th at the JP Morgan Healthcare Conference in San Francisco.

Under the terms of the agreement, Pillar Biosciences will create a joint venture company with CBSH’s subsidiary Central Laboratory (Holdings) Limited to provide precision diagnostic products and services to Hong Kong, Macau, South Korea, and Southeast Asia. Furthermore, the joint venture company will distribute Pillar Biosciences’ products including the SLIMamp® and PiVAT® based cancer panels in parts of China. As part of the agreement, CBSH will participate in Pillar Biosciences’ Series B financing round that was initially closed in November 2018.

“Historically, patient samples had to be shipped from Hong Kong to the United States or other countries for genetic analysis, which increased the costs and limited the accuracy of these types of tests,” said Dr. Gang Song, founder and CEO of Pillar Biosciences. “We are excited to partner with CBSH to deliver economical and accurate cancer diagnostic products and services to patients in Hong Kong and many regions of Southeast Asia.”

Press Contact:

William Wright
Director of Sales
wrightw@pillar-biosciences.com
pr@pillar-biosciences.com

About Pillar Biosciences

Pillar Biosciences is a clinical cancer diagnostics company based in Boston, Massachusetts and in Shanghai, China. We create precision NGS panels and software solutions to make clinical NGS robust, streamlined and cost-effective. Our SLIMamp®- and PiVAT®-based products are intended to deliver the most value to high-throughput reference laboratories and clinical oncology laboratories. Learn more at https://pillar-biosciences.com.

About China Biotech Services Holdings, Ltd

The goal of CBSH is to deliver accurate disease detection to a vast patient population by developing a large health system with cutting-edge technologies and service distribution channels. CBSH’s subsidiary Central Laboratory (Holdings) Limited is a Hong Kong-based clinical testing company with a third-party pathological testing lab (PHC), which was established in 1969 that has broad brand awareness and a large network of customers and cooperative organizations in Hong Kong.

Pillar in the News

December 11, 2017
Pillar Biosciences Announces Issuance of China and U.S. Patents Covering SLIMamp™ Technology

NATICK MASSACHUSETTS, Dec. 11, 2017 /PRNEWSWIRE/ – Pillar Biosciences, Inc. a manufacturer of precision next-generation sequencing (NGS) panels and software solutions for robust and cost-effective clinical sequencing, announces that key [more]

NATICK MASSACHUSETTS, Dec. 11, 2017 /PRNEWSWIRE/ – Pillar Biosciences, Inc. a manufacturer of precision next-generation sequencing (NGS) panels and software solutions for robust and cost-effective clinical sequencing, announces that key patents covering its SLIMamp™ technology have been issued in its most important markets China and the United States. The State Intellectual Property Office (SIPO) of the People’s Republic of China issued patent ZL201680001111.1 with a duration of 20 years. Building on a prior March 2017 approval by the United States Patent and Trademark Office (USPTO) (U.S. Patent No. 9,605,305, “Method for reducing primer-dimer amplification”), this technology is central to Pillar Biosciences’ vision of enabling affordable precision medicine by simplifying the sample processing workflow while simultaneously improving assay reliability and lowering costs.

“This patent issuance in China is a significant milestone for Pillar Biosciences,” said Gang Song, Ph.D., CEO of Pillar Biosciences. “We are pleased that the SIPO recognizes this fundamental innovation to streamline and accelerate the pace of adoption of precision medicine in mainland China by offering intellectual property protection to this substantial and fast-growing market”, Dr. Song added.

Pillar Biosciences’ SLIMamp technology reduces the time and effort of targeted sequencing enrichment down to a single-day, single-well per sample workflow with minimal sample input (as little as 2.5 nanograms of nucleic acid, or the equivalent of 700 cells). Limited amounts of input material are often challenging for clinical oncology laboratories, and alternative approaches may often take several days to perform.

“With the key US and China patents being issued and a current product portfolio of research use only targeted enrichment kits that include the ONCO/Reveal BRCA1 & BRCA2 Panel, a Lung and Colon Cancer Hotspot Panel, and a multi-cancer Solid Tumor Hotspot Panel, we expect to launch several exciting products in 2018 including one for liquid biopsy” said Manfred Scholz, Ph.D., Head of Corporate Development at Pillar Biosciences. “We are an innovative, technology-driven company that works with clinical, commercial, and technology partners on enabling affordable precision medicine in major global markets.”

About Pillar Biosciences

Pillar Biosciences is a clinical cancer diagnostics company. We create precision next-generation sequencing (NGS) panels and software solutions to make clinical NGS robust, streamlined and cost-effective. Our SLIMamp™- and PiVAT™-based products are intended to deliver the most value to high-throughput reference labs and clinical oncology laboratories. To learn more, visit https://pillar biosciences.com.

Press Contact:

pr@pillar-biosciences.com

Pillar in the News

November 29, 2017
Pillar Biosciences announces ISO 13485:2016 Certification

NATICK MASSACHUSETTS, Nov. 29, 2017 /PRNEWSWIRE/ – Pillar Biosciences, Inc. a manufacturer of precision next-generation sequencing (NGS) panels and software solutions for robust and cost-effective clinical sequencing, announces it has [more]

NATICK MASSACHUSETTS, Nov. 29, 2017 /PRNEWSWIRE/ - Pillar Biosciences, Inc. a manufacturer of precision next-generation sequencing (NGS) panels and software solutions for robust and cost-effective clinical sequencing, announces it has received ISO 13485:2016 certification for design, development, manufacture, and distribution of products for the clinical oncology laboratory within a comprehensive quality management system (QMS). The first Pillar Biosciences assay produced under this QMS is the recently-launched ONCO/Reveal BRCA 1/2 panel targeting the entire coding region of the BRCA genes. All current products are based upon Pillar Biosciences’ patented SLIMamp™ targeted sequencing technology platform and proprietary PiVAT™ analytics software. While current products are for research use only (RUO), Pillar intends to file selected targeted NGS panels with proven clinical utility for regulatory approval.

The ISO 13485:2016 certificate was issued to Pillar Biosciences by Intertek on November 24, 2017. Pillar Biosciences’ Quality Management System will assure the quality and efficacy of its products and services in accordance to applicable regulatory and statutory requirements.

Gang Song, Ph.D., CEO, stated “Pillar Biosciences is enabling affordable precision medicine by producing products for the clinical NGS laboratory that are accurate, streamlined, reliable and cost-effective. Our customers can be confident that Pillar Biosciences’ future RUO and Illumina MiSeq™ Dx in vitro diagnostic products are developed, manufactured, and distributed under the most recent quality standards.”

About Pillar Biosciences

Pillar Biosciences is a clinical cancer diagnostics company. We create precision next-generation sequencing (NGS) panels and software solutions to make clinical NGS robust, streamlined and cost-effective. Our SLIMamp™- and PiVAT™-based products are intended to deliver the most value to high-throughput reference labs and clinical oncology laboratories. To learn more, visit https://pillar‑biosciences.com.

Press Contact:

pr@pillar-biosciences.com

Pillar in the News

October 26, 2017
Pillar Biosciences to Collaborate with Illumina on Next-Generation Sequencing Based In Vitro Diagnostics Development

Illumina and Pillar Biosciences, Inc. today announced an agreement to develop next-generation sequencing (NGS) based in vitro diagnostic (IVD) tests. Under the terms of the agreement, Pillar Biosciences will lead [more]

Illumina and Pillar Biosciences, Inc. today announced an agreement to develop next-generation sequencing (NGS) based in vitro diagnostic (IVD) tests. Under the terms of the agreement, Pillar Biosciences will lead the development of a series of diagnostic tests that will be run on the Illumina MiSeq™Dx instrument.

Pillar Biosciences has developed Stem Loop Inhibition Mediated Amplification (SLIMamp®), an innovative technology to maximize the efficiency and performance of targeted NGS panels for the clinical user.

Gang Song, Ph.D., CEO of Pillar Biosciences, stated: “The combination of two state-of the-art NGS technologies, SLIMamp and MiSeqDx, will enable affordable precision medicine and make NGS accessible to clinical laboratories.”

The SLIMamp technology is optimized for highly multiplexed reactions from a single tube with as little as 2.5 ng of DNA, supporting sequencing from FFPE and biofluids. Specifically designed to enable automation, it offers a unique technology that can leverage the power of the MiSeqDx to provide superior uniformity and specificity. SLIMamp based NGS panels provide highly sensitive variant detection in regions of interest including GC-rich regions and low quality samples. Pillar intends to submit multiple NGS assays to the FDA starting in 2018.

About Pillar Biosciences

Pillar Biosciences is a clinical cancer diagnostics company. We create precision NGS panels and software solutions to make clinical NGS fast and cost-effective. Our SLIMamp based products are intended to deliver the most value to high-throughput reference labs and clinical oncology labs. To learn more, visit https://pillar-biosciences.com/.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.

Pillar in the News

May 11, 2016
ORI Healthcare Fund Invests in Pillar Biosciences

HONG KONG, CHINA—(Marketwired - May 11, 2016) - ORI Healthcare Fund L.P. (ORI Fund) announces the completion of US$18 million investment into Pillar Biosciences Inc., a Boston-based start-up specialized in next generation sequencing ("NGS")-based clinical oncology testing in order to bring affordable precision medicine to cancer patients globally. [more]

HONG KONG, CHINA—(Marketwired - May 11, 2016) - ORI Healthcare Fund L.P. (ORI Fund) announces the completion of US$18 million investment into Pillar Biosciences Inc., a Boston-based start-up specialized in next generation sequencing ("NGS")-based clinical oncology testing in order to bring affordable precision medicine to cancer patients globally.

Pillar Biosciences is prized with its patent-pending targeted sequencing technology platform and a proprietary data analysis toolkit, which achieve high sensitivity and specificity with clinical samples. The platform provides a fast, simple and affordable targeted sequencing method for NGS-based oncology testing. The start-up has also released its beta version of Lung & Colon Cancer Somatic Mutation Panel and BRCA1 & BRCA2 Germline Mutation Panel to cancer centers and clinical testing companies in US and China for validation studies.

The investment from ORI Fund will help the company continue its R&D efforts in tumor tissue genotyping area, i.e. integration of back-end information analytics capability, as well as adding liquid biopsy products for cancer therapeutic decision-making and treatment monitoring.

ORI Capital, the manager of ORI Fund, believes that NGS-based oncology testing is an integral component of precision cancer therapeutics and it helps to make steady advances in the molecular diagnosis of cancers. In particular, NGS makes it possible to detect cancer in early stages by directly measuring circulating tumor DNA.

The transaction is consistent with ORI Fund's investment focus in the clinical oncology space. "We are excited to partner with Pillar Biosciences to further advance the modern cancer treatment, which is the main focus of our fund," commented Ms. Simone Song, Senior Partner of ORI Fund. "We hope the partnership between us will help speed up the development of affordable precision treatments for cancer patients worldwide."

About ORI Healthcare Fund

ORI Fund is a US$200 million venture capital fund focused on investing in innovative companies with disruptive technologies in the healthcare industry globally. The fund is founded by Ms. Simone (Hong Fang) Song, former investment banker and head of China Healthcare at Goldman Sachs. The team consists mostly of former Goldman Sachs bankers and healthcare scientists.

Events

Meet Pillar Biosciences at any of the following conferences

2019 CGC Annual Meeting | Nashville, TN | August 11-14, 2019

 [more]

At the Cancer Genomics Consortium Annual Meeting join friends, colleagues, and mentors to learn about clinical practices relevant to your laboratory and to consider how to shape laboratory genomics moving forward.

Next Generation Dx Summit | Washington, DC | August 20-22, 2019

 [more]

The Next Generation Dx Summit is a comprehensive event for diagnostics professionals to build partnerships, gain industry knowledge, and network with peers. Visit us at booth 214!

Annual Meeting of the Chinese Society of Clinical Oncology | Xiamen, China | September 18-22, 2019

 [more]

The theme of the 22nd Annual Meeting of the Chinese Society of Clinical Oncology is “Precision & Intelligence: Hope to conquer cancer.” The goals of CSCO are to standardize comprehensive treatment, encourage innovation in clinical research, and promote the development of clinical oncology.

ASHG Annual Meeting | Houston, TX | October 15-19, 2019

 [more]

ASHG 2019 is the largest human genetics meeting and exposition in the world. This year’s meeting is expected to attract over 6,500 scientific attendees. The meeting provides a forum for the presentation and discussion of cutting-edge science in all areas of human genetics. Visit us at booth #505.

DxPx Conference 2019 | Dusseldorf, Germany | November 18, 2019

 [more]

The Diagnostics Partnering Conference brings together the world’s best Dx startups, the most innovative Dx corporations, and the most Dx-focused investors to adapt the successful pharma partnering concept to the specific needs of the diagnostics and research tools industry.